公开(公告)号：EP2170944A1

公开(公告)日：2010-04-07

申请号：EP08775781.1

申请日：2008-06-27

申请人： KINGS COLLEGE LONDON

发明人： PEAKMAN, Mark ,  CALVINO, Ruben Varela

IPC分类号： C07K14/62 ,  C07K7/06 ,  A61K38/28 ,  A61K38/08 ,  G01N33/68

CPC分类号： C07K14/62 ,  A61K38/00 ,  C07K7/06 ,  G01N33/505 ,  G01N33/6893 ,  G01N2800/042

摘要： The present invention provides isolated preproinsulin-derived peptides of 8 or 9 amino acids, comprising the amino acid sequence WGPDPAA (SEQ ID NO: 1), isolated Class I peptide-HLA complexes presenting said peptides and isolated molecules having binding affinity for said peptides and/or said peptide-HLA complexes. Such compositions are useful in the treatment of Type 1 diabetes mellitus (TlDM)

公开(公告)号：EP4031161A1

公开(公告)日：2022-07-27

申请号：EP20780278.6

申请日：2020-09-16

申请人： Kings College London

发明人： PEAKMAN, Mark ,  VERHAGEN, Johan ,  EICHMANN, Martin

IPC分类号： A61K38/10 ,  A61K38/28 ,  A61K39/00 ,  A61P3/10 ,  C07K14/625 ,  G01N33/50

公开(公告)号：EP3307298A1

公开(公告)日：2018-04-18

申请号：EP16729347.1

申请日：2016-06-10

申请人： Kings College London

发明人： PEAKMAN, Mark

IPC分类号： A61K38/10 ,  A61K38/16 ,  A61K38/28 ,  A61P3/10 ,  G01N33/68

摘要： The invention relates to a specific peptide combination. The peptide combination may be present in a pharmaceutically acceptable composition. The peptide combination can be used in the therapy or prevention of Type 1 Diabetes (TID). The invention also relates to a method of diagnosing or determining treatment efficacy, the method utilising the specific peptide combination.

公开(公告)号：EP2170944B1

公开(公告)日：2014-04-09

申请号：EP08775781.1

申请日：2008-06-27

申请人： KINGS COLLEGE LONDON

发明人： PEAKMAN, Mark ,  CALVINO, Ruben Varela

IPC分类号： G01N33/50 ,  G01N33/68

CPC分类号： C07K14/62 ,  A61K38/00 ,  C07K7/06 ,  G01N33/505 ,  G01N33/6893 ,  G01N2800/042

公开(公告)号：EP3307298B1

公开(公告)日：2020-01-15

申请号：EP16729347.1

申请日：2016-06-10

申请人： Kings College London

发明人： PEAKMAN, Mark

IPC分类号： A61K38/16 ,  A61K38/28 ,  A61P3/10 ,  G01N33/68

公开(公告)号：EP1709070A1

公开(公告)日：2006-10-11

申请号：EP05701998.6

申请日：2005-01-24

申请人： KINGS COLLEGE LONDON

发明人： PEAKMAN, Mark

IPC分类号： C07K14/47 ,  A61K39/00 ,  C07K14/62

CPC分类号： C07K14/4713 ,  A61K38/00 ,  C07K14/62

摘要： Peptides for use in the therapy or prevention of Type 1 Diabetes mellitus (TIDM) are those having sequences containing QPLALEGSLQK (SEQ ID NO: 9). j Examples are those having a sequence selected from the group consisting 10 essentially of GGGPGAGSLQPLALEGSLQK (SEQ ID NO: 4), GSLQPLALEGSLQKRGIV (SEQ ID NO: 5), and QPLALEGSLQKRGIVEQ (SEQ ID NO: 6). One or more of the above peptides may be combined with one or more peptides having a sequence or sequences consisting essentially of sequences selected from LAKEWQALCAYQAEPNTCATAQGI?GNIK (SEQ ID NO: 11), KLKVESSPSRSDYINASPIIEHDP (SEQ ID NO: 12), and SFYLKNVQTQETRTLTQFHF (SEQ ID NO: 13). Also disclosed is a method of assessing the potential of a peptide for TIDM therapy or prevention which comprises subjecting the candidate peptide to a frst assay indicative of a pathogenic T cell response in blood or other biological sample, such as an ELISPOT assay for IFN-y. In the case of a positive response to the first assay, the candidate peptide is subjected to a second assay indicative of a regulatory T cell response to the peptide, such as an ELISPOT assay for IL­ 10).